Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Rhea-AI Summary

Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York City. Christopher U. Missling, PhD, President and CEO of Anavex, will present on Monday, September 9, 2024, at 11:30 a.m. ET at the Lotte New York Palace.

The presentation will be available via audio webcast on the company's website. Additionally, Dr. Missling will participate in a panel discussion on 'Non-Amyloid-Targeted Approaches in Treatment of Alzheimer's Disease' on September 10, 2024 at 2:00 p.m. ET. Anavex focuses on developing therapeutics for various CNS diseases, including Alzheimer's, Parkinson's, and Rett syndrome.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 26^th Annual Global Investment Conference, being held September 9-11, 2024 in New York City.

The presentation will take place on Monday, September 9, 2024, at 11:30 a.m. ET at the Lotte New York Palace in New York, NY. An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day.

In addition, Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a panel titled “Non-Amyloid-Targeted Approaches in Treatment of Alzheimer’s Disease” taking place September 10, 2024 at 2:00 p.m. ET at the Lotte New York Palace in New York, NY.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX^®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX^®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX^®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX^®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX^®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

When is Anavex Life Sciences (AVXL) presenting at the H.C. Wainwright Global Investment Conference 2024?

Anavex Life Sciences (AVXL) is presenting on Monday, September 9, 2024, at 11:30 a.m. ET at the Lotte New York Palace in New York City.

What panel is Anavex's CEO participating in at the H.C. Wainwright conference?

Christopher U. Missling, PhD, CEO of Anavex, will participate in a panel titled 'Non-Amyloid-Targeted Approaches in Treatment of Alzheimer's Disease' on September 10, 2024 at 2:00 p.m. ET.

How can investors access Anavex's (AVXL) presentation at the H.C. Wainwright conference?

Investors can access an audio webcast of Anavex's presentation through the Investors section of the company's website at www.anavex.com. A replay will be available later that day.

What diseases does Anavex Life Sciences (AVXL) focus on in its drug development?

Anavex Life Sciences (AVXL) focuses on developing therapeutics for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental and neurodegenerative diseases, rare diseases including Rett syndrome, and other central nervous system (CNS) diseases.